CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility

Cancer Research

Volumn 73, Issue 2, 2013, Pages 561-570

  Girbl, Tamara ^a   Hinterseer, Elisabeth ^a   Grössinger, Eva Melanie ^a   Asslaber, Daniela ^a   Oberascher, Karin ^b   Weiss, Lukas ^a   Hauser Kronberger, Cornelia ^a   Neureiter, Daniel ^a   Kerschbaum, Hubert ^b   Naor, David ^c   Alon, Ronen ^d   Greil, Richard ^a   Hartmann, Tanja Nicole ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CD44V ANTIGEN; HERMES ANTIGEN; HYALURONIC ACID; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ARTICLE; CELL ACTIVATION; CELL INTERACTION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKOCYTE ADHERENCE; LYMPH NODE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ANTIGENS, CD40; CD40 LIGAND; CELL MOVEMENT; CHEMOKINE CCL21; HUMANS; HYALURONIC ACID; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; LYMPHOCYTE ACTIVATION; TUMOR CELLS, CULTURED;

EID: 84872526123     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2749     Document Type: Article

References (39)

1. Deaglio S, Malavasi F. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica 2009;94: 752-6.
2. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117: 563-74.
3. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-83.
4. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111: 5173-81.
5. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117: 5463-72.
6. Tinhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R. Difference in the relative distribution of CD4+ T-cell subsets in BCLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J Immunother 2009;32: 302-9.
7. Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992;80: 3173-81.
8. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40- ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106: 995-1004.
9. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176: 1319-26.
10. Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Ivanyi J, Schmitz G, et al. Different proliferative and survival capacity of CLLcells in a newly established in vitro model for pseudofollicles. Leukemia 2009;23: 2118-28.
11. Pereira JP, Kelly LM, Cyster JG. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol 2010;22: 413-9.
12. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286: 2098-102.
13. Johrer K, Hofbauer SW, Zelle-Rieser C, Greil R, Hartmann TN. Chemokine- dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention? Expert Opin Biol Ther 2012;12: 425-41.
14. Wallach-Dayan SB, Grabovsky V, Moll J, Sleeman J, Herrlich P, Alon R, et al. CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. J Cell Sci 2001;114: 3463-77.
15. Bennett KL, Modrell B, Greenfield B, Bartolazzi A, Stamenkovic I, Peach R, et al. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol 1995;131: 1623-33.
16. Maiti A, Maki G, Johnson P. TNF-alpha induction of CD44-mediated leukocyte adhesion by sulfation. Science 1998;282: 941-3.
17. De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia 1997;11: 134-41.
18. Eisterer W, Bechter O, Soderberg O, Nilsson K, Terol M, Greil R, et al. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res 2004;28: 1043-51.
19. Zarcone D, De Rossi G, Tenca C, Marroni P, Mauro FR, Cerruti GM, et al. Functional and clinical relevance of CD44 variant isoformexpression on B-cell chronic lymphocytic leukemia cells. Haematologica 1998;83: 1088-98.
20. Jaganathan BG, Ruester B, Dressel L, Stein S, Grez M, Seifried E, et al. Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells 2007;25: 1966-74.
21. Desch P, Asslaber D, Kern D, Schnidar H, Mangelberger D, Alinger B, et al. Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene 2010;29: 4885-95.
22. van Weering DH, Baas PD, Bos JL. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 1993;3: 100-6.
23. Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, Holler C, et al. Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 2008;86: 541-52.
24. Till KJ, Zuzel M, Cawley JC. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res 1999;59: 4419-26.
25. Bajenoff M, Egen JG, Koo LY, Laugier JP, Brau F, Glaichenhaus N, et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 2006;25: 989-1001.
26. Li S, Guan JL, Chien S. Biochemistry and biomechanics of cell motility. Annu Rev Biomed Eng 2005;7: 105-50.
27. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44in cancer. Crit Rev Clin Lab Sci 2002;39: 527-79.
28. Molica S, Vitelli G, Levato D, Giannarelli D, Gandolfo GM. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer 2001;92: 713-9.
29. Vagima Y, Avigdor A, Goichberg P, Shivtiel S, Tesio M, Kalinkovich A, et al.MT1-MMPandRECKare involvedin humanCD34+progenitor cell retention, egress, and mobilization. J Clin Invest 2009;119: 492-503.
30. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106: 1824-30.
31. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114: 4441-50.
32. Herishanu Y, Gibellini F, Njuguna N, Hazan-Halevy I, Farooqui M, Bern S, et al. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma 2011;52: 1758-69.
33. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100: 1795-801.
34. Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA, del Cerro MH, Van den Steen PE, Opdenakker G, et al. Alpha4beta1 integrin and 190- kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008; 112: 169-78.
35. Redondo-Munoz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernandez del Cerro M, Roderfeld M, et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010;17: 160-72.
36. Giannopoulos K, Mertens D, Buhler A, Barth TF, Idler I, Moller P, et al. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 2009;23: 519-27.
37. Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A 2004;101: 18081-6.
38. Naor D, Nedvetzki S, Walmsley M, Yayon A, Turley EA, Golan I, et al. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann N Y Acad Sci 2007;1110: 233-47.
39. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010;46: 1271-7.